| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
47,262,000 |
| Market
Cap: |
11.05(B) |
| Last
Volume: |
369,691 |
Avg
Vol: |
419,170 |
| 52
Week Range: |
$205.19 - $256.94 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile United Therapeutics is a biotechnology company. Through its subsidiary, Lung Biotechnology PBC, Co. is focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Co. markets and sells the following commercial therapies to treat pulmonary arterial hypertension: Remodulin® (treprostinil) Injection; Tyvaso® (treprostinil) Inhalation Solution; Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, for the treatment of high-risk neuroblastoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
458,205 |
492,210 |
585,467 |
1,744,588 |
| Total Sell Value |
$108,580,139 |
$116,427,987 |
$137,373,790 |
$425,241,289 |
| Total People Sold |
5 |
6 |
6 |
10 |
| Total Sell Transactions |
46 |
54 |
71 |
244 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-18 |
4 |
AS |
$226.37 |
$1,814,271 |
D/D |
(8,000) |
130 |
|
0% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-18 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-17 |
4 |
AS |
$230.02 |
$1,843,763 |
D/D |
(8,000) |
130 |
|
0% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-17 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-14 |
4 |
AS |
$227.90 |
$1,827,876 |
D/D |
(8,000) |
130 |
|
1% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-14 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Dwek Raymond |
|
– • – |
2023-04-14 |
4 |
D |
$228.72 |
$457,440 |
D/D |
(2,000) |
0 |
|
- |
|
| Dwek Raymond |
|
– • – |
2023-04-14 |
4 |
OE |
$63.90 |
$127,800 |
D/D |
2,000 |
2,000 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-13 |
4 |
AS |
$225.80 |
$1,845,541 |
D/D |
(8,000) |
130 |
|
-0% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-13 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-12 |
4 |
AS |
$225.71 |
$1,817,199 |
D/D |
(8,000) |
130 |
|
2% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-12 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-11 |
4 |
AS |
$222.83 |
$1,804,555 |
D/D |
(8,000) |
130 |
|
2% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-11 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Dwek Raymond |
|
– • – |
2023-04-10 |
4 |
D |
$223.07 |
$669,210 |
D/D |
(3,000) |
0 |
|
- |
|
| Dwek Raymond |
|
– • – |
2023-04-10 |
4 |
OE |
$63.90 |
$191,700 |
D/D |
3,000 |
3,000 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-10 |
4 |
AS |
$222.70 |
$1,793,684 |
D/D |
(8,000) |
130 |
|
2% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-10 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-06 |
4 |
AS |
$226.77 |
$1,832,925 |
D/D |
(8,000) |
130 |
|
2% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-06 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2023-04-06 |
4 |
AS |
$231.93 |
$1,396,755 |
D/D |
(6,000) |
36,599 |
|
2% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2023-04-06 |
4 |
OE |
$120.26 |
$721,560 |
D/D |
6,000 |
42,599 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-05 |
4 |
AS |
$228.40 |
$1,850,776 |
D/D |
(8,000) |
130 |
|
1% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-05 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-04 |
4 |
AS |
$223.52 |
$1,810,064 |
D/D |
(8,000) |
130 |
|
3% |
|
4998 Records found
|
|
Page 9 of 200 |
|
|
2.10 (0.89%) 
